Drug · DIN 02417170
CONSTELLA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since December 15, 2023; first marketed December 17, 2014.
- Drug Identification Number (DIN)
- 02417170
- Company (DIN owner)
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Linaclotide A06AX04
- Class
- Human
- Record last updated
- July 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LINACLOTIDE | 290 MCG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 18, 2022: NOC 29224New Drug Submission (NDS) · Administrative: Merger/Buy-out
- December 2, 2013: NOC 14972New Drug Submission (NDS)
Other DINs named CONSTELLA
- DIN 02417162 · Marketed
- DIN 02469510 · Marketed